Navigation Links
Blood Cancer Drug Shows Promise Against Lupus

Experiments with mice found Velcade reduced dangerous autoantibodies

SUNDAY, June 8 (HealthDay News) -- A drug used to treat multiple myeloma, a cancer of the white blood cells, may also be a treatment for the chronic autoimmune disease lupus, German researchers report.

The drug, Velcade (bortezomib), which is a proteasome inhibitor, worked against the disease and prolonged survival in mice with lupus. The finding could one day offer treatment options for other antibody-associated diseases, too, the researchers said.

"Autoantibody-mediated diseases such as autoimmune hemolytic anemia, immune thrombocytopenia, myasthenia gravis and systemic lupus erythematosus are often difficult to treat," said lead researcher Dr. Reinhard Voll, of the University of Erlangen-Nuremberg.

A big problem is that plasma cells, which are the predominant producers of the disease-causing autoantibodies, can't be efficiently attacked with current treatments, Voll said.

Lupus is a so-called autoimmune disease in which the immune system attacks healthy cells and tissues by mistake, leading to damage to joints, skin, blood vessels and organs. There are many kinds of lupus, with the most common type being systemic lupus erythematosus, which affects many parts of the body. There's no one test to diagnose lupus, and it may take months or years to make the diagnosis. There's also no cure, but medicines and lifestyle changes can help control the disease, according to the U.S. National Institutes of Health

For the new study, Voll's team found that bortezomib efficiently eliminated the plasma cells in the mice, leading to a drastic decrease in autoantibodies and prolonged survival. And, the drug had no effect on other cells, he said.

"Proteasome inhibitors may be beneficial in refractory human diseases caused predominantly by autoantibodies," Voll said. "Proteasome inhibitors can selectively deplete plasma cells, which are resistant to current treatments."

Outside experts were divided on the findings, published in the June 8 online edition of Nature Medicine.

"This is a very exciting study that explores a novel mechanism for treating lupus erythematosus," said Dr. Jennifer Grossman, an assistant professor of medicine at the University of California, Los Angeles.

"The fact that antibodies almost completely disappeared is encouraging. I look forward to hearing more about this treatment in the future," she said.

But, another expert expressed concern that the treatment could adversely affect other cells in the human body.

"I think they're onto something important, it looks as if it has a remarkable therapeutic effect," said Dr. Noel Rose, director of the Autoimmune Disease Research Center at Johns Hopkins University. "The downside is that this is a proteasome inhibitor, and there is no reason to think that it would be specific for plasma cells. It does affect other rapidly proliferating cells."

Rose noted that many drugs may appear safe during an initial trial. "I'm still really suspicious that if this is used clinically, there are going to be side effects like effects on intestinal or other rapidly dividing cells," he said. "The question is, are the side effects going to be severe enough to prevent the use of this drug?"

More information

To learn more about lupus, the U.S. National Library of Medicine.

SOURCES: Reinhard Voll, M.D., University of Erlangen-Nuremberg, Erlangen, Germany; Jennifer Grossman, M.D., assistant professor of medicine, University of California, Los Angeles; Noel Rose, M.D., director, Autoimmune Disease Research Center, Johns Hopkins University, Baltimore; June 8, 2008, Nature Medicine, online

Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Having heart surgery? Watch your blood sugar, especially if youre overweight or older
2. Scientists ID Gene Regulating Blood Glucose Levels
3. Studies Differ on Benefits of Aggressive Blood Sugar Control
4. MultiVu Video Feed: Study in the New England Journal of Medicine Shows High Blood Pressure Drug Tekturna(R) Reduces Key Marker of Kidney Disease
5. Can SonicMood Help to Significantly Lower High Blood Pressure? The Latest Research Answers With a Resounding YES!
6. New Yorks Catholic Archdiocese Hosting June 2 Blood Drive
7. Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese
8. Special supplement on self-monitoring of blood glucose in diabetes technology & therapeutics
9. Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics
10. No association found between vitamin D concentration in blood and risk of prostate cancer
11. International Research Organization Responds to Recent Studies Purporting to Show That Transfusion of Older Red Blood Cells Leads to Greater Risk
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is ... Pro X. With ProSidebar: Fasion, video editors can easily add an informative sidebar ... minimalist title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... ... 27, 2015 , ... Keeping in mind challenges faced by ... wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for ... parents and bring advice from parenting experts within their reach. As a part ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap and ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s Santa ... and Sepsis conditions present in similar ways and require time-critical intervention to avoid large ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
Breaking Medicine Technology: